Literature DB >> 8297920

Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.

B E Murphy1, D Filipini, A M Ghadirian.   

Abstract

The rationale for the use of anti-glucocorticoids in the treatment of major depression has been reviewed. Four patients with chronic severe depression who were resistant to conventional therapies were given RU 486 (200 mg/day) for periods up to eight weeks. Substantial levels of RU 486 were achieved within the first few days, and the levels fell gradually over the week after the treatment was discontinued. In three cases, treatment was stopped before the eight weeks were completed: in one case because of the appearance of a rash, in the others because of side-effects, which, in retrospect, were likely unrelated to the drug. The mean scores on the Hamilton Rating Scale for Depression of three patients decreased. Levels of adrenocorticotrophin, dehydroepiandrosterone and cortisol rose during treatment. These preliminary results suggest that glucocorticoid antagonists may be effective in the treatment of major depression and merit further exploration.

Entities:  

Keywords:  Biology; Case Histories; Clinical Research; Depression; Diseases; Endocrine System; Hormone Antagonists; Hormones; Mental Disorders; Physiology; Research Report; Ru-486--administraction and dosage; Treatment

Mesh:

Substances:

Year:  1993        PMID: 8297920      PMCID: PMC1188541     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  13 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

Review 2.  Steroids and depression.

Authors:  B E Murphy
Journal:  J Steroid Biochem Mol Biol       Date:  1991-05       Impact factor: 4.292

3.  Treatment of major depression with steroid suppressive drugs.

Authors:  B E Murphy
Journal:  J Steroid Biochem Mol Biol       Date:  1991-08       Impact factor: 4.292

4.  Glucocorticoid receptors and depression.

Authors:  L J Whalley; N Borthwick; D Copolov; H Dick; J E Christie; G Fink
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-29

5.  Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis.

Authors:  L M Kettel; A A Murphy; J F Mortola; J H Liu; A Ulmann; S S Yen
Journal:  Fertil Steril       Date:  1991-09       Impact factor: 7.329

6.  RU 38486: a potent antiglucocorticoid in vitro and in vivo.

Authors:  D Gagne; M Pons; D Philibert
Journal:  J Steroid Biochem       Date:  1985-09       Impact factor: 4.292

7.  Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test.

Authors:  G J Gormley; M T Lowy; A T Reder; V D Hospelhorn; J P Antel; H Y Meltzer
Journal:  Am J Psychiatry       Date:  1985-11       Impact factor: 18.112

8.  RU486 in depression.

Authors:  K R Krishnan; D Reed; W H Wilson; W B Saunders; J C Ritchie; C B Nemeroff; B J Carroll
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1992       Impact factor: 5.067

9.  Response to steroid suppression in major depression resistant to antidepressant therapy.

Authors:  B E Murphy; V Dhar; A M Ghadirian; G Chouinard; R Keller
Journal:  J Clin Psychopharmacol       Date:  1991-04       Impact factor: 3.153

10.  Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain.

Authors:  A Peiffer; S Veilleux; N Barden
Journal:  Psychoneuroendocrinology       Date:  1991       Impact factor: 4.905

View more
  21 in total

Review 1.  [New developments in pharmacotherapy of depression].

Authors:  R Rupprecht; Th C Baghai; H-J Möller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

Review 2.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?

Authors:  Mitchel A Kling; Victoria H Coleman; Jay Schulkin
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

4.  Advances in the Management of Treatment-Resistant Depression.

Authors:  Paul E Holtzheimer
Journal:  Focus (Am Psychiatr Publ)       Date:  2010

5.  Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.

Authors:  L H Price; R T Malison; C J McDougle; G H Pelton
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

6.  Regulation of corticosteroid receptor gene expression in depression and antidepressant action.

Authors:  N Barden
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 8.  Novel targets for antidepressant therapies.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

Review 9.  Advances in the treatment of depression.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  NeuroRx       Date:  2006-01

Review 10.  Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.

Authors:  Nicholas Barden
Journal:  J Psychiatry Neurosci       Date:  2004-05       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.